Treatment of Unresectable Primary and Metastatic Live
Microspheres (TheraSphereÂ®): Assessment of Hepatic

CardioVascular and Interventional Radiology

29, 522-529

DOI: 10.1007/s00270-005-0171-4

Citation Report

#	Article	IF	Citations
1	Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. Journal of Vascular and Interventional Radiology, 2006, 17, 1251-1278.	0.2	619
2	Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. Journal of Vascular and Interventional Radiology, 2006, 17, 1571-1593.	0.2	201
3	Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. Journal of Vascular and Interventional Radiology, 2006, 17, 1425-1439.	0.2	189
4	Yttrium-90 microspheres (TheraSphereÂ®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. Journal of Surgical Oncology, 2006, 94, 572-586.	0.8	297
5	Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET. American Journal of Roentgenology, 2007, 188, 776-783.	1.0	117
6	Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2007, 41, 839-854.	1.1	15
7	Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. European Journal of Surgical Oncology, 2007, 33, 597-602.	0.5	44
8	Gastrointestinal Complications Associated with Hepatic Arterial Yttrium-90 Microsphere Therapy. Journal of Vascular and Interventional Radiology, 2007, 18, 553-561.	0.2	163
9	Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications. Journal of Biomedical Materials Research - Part A, 2007, 82A, 892-898.	2.1	33
10	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 2008, 47, 71-81.	3.6	542
11	Hepatitis B Virus Reactivation After Three-Dimensional Conformal Radiotherapy in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 813-819.	0.4	93
12	Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(l-lactic acid) microspheres in healthy pigs. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1259-1271.	3.3	46
13	Evaluation of Hepatic Angiography Procedures and Bremsstrahlung Imaging in Selective Internal Radiation Therapy: A Two-Year Single-Center Experience. CardioVascular and Interventional Radiology, 2008, 31, 643-649.	0.9	10
14	Treatment of unresectable cholangiocarcinoma using yttriumâ€90 microspheres. Cancer, 2008, 113, 2119-2128.	2.0	182
15	Unresectable Chemorefractory Liver Metastases: Radioembolization with⁹⁰Y Microspheresâ€"Safety, Efficacy, and Survival. Radiology, 2008, 247, 507-515.	3.6	207
16	Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability. Nuclear Medicine and Biology, 2008, 35, 227-232.	0.3	20
17	Radioembolization of Yttrium-90 Microspheres for Hepatic Malignancy. Seminars in Interventional Radiology, 2008, 25, 048-057.	0.3	47
18	Which Arteries Are Expendable? The Practice and Pitfalls of Embolization throughout the Body. Seminars in Interventional Radiology, 2008, 25, 191-203.	0.3	23

#	Article	IF	Citations
19	Experience With More Than 500 Minimally Invasive Hepatic Procedures. Annals of Surgery, 2008, 248, 475-486.	2.1	328
20	Complications of Therapeutic Endovascular Procedures in Malignant Liver Diseases. , 2008, , 589-598.		0
21	Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology, 2009, 49, 1185-1193.	3.6	229
22	Reply:. Hepatology, 2009, 50, 653-653.	3.6	2
23	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer, 2009, 115, 616-623.	2.0	403
24	Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdominal Imaging, 2009, 34, 566-581.	2.0	88
25	Biocompatibility, Inflammatory Response, and Recannalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings. CardioVascular and Interventional Radiology, 2009, 32, 727-736.	0.9	74
26	Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1494-1500.	0.4	238
27	Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. European Radiology, 2009, 19, 951-959.	2.3	199
28	Treatment of Hepatocellular Carcinoma by Radioembolization Using ⁹⁰Y Microspheres. Digestive Diseases, 2009, 27, 164-169.	0.8	30
29	Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. European Journal of Radiology, 2009, 69, 114-119.	1.2	13
30	Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. Journal of Vascular and Interventional Radiology, 2009, 20, 1557-1563.	0.2	31
31	Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. Journal of Vascular and Interventional Radiology, 2009, 20, 1121-1130.	0.2	305
32	Salvage Therapy for Liver-dominant Colorectal Metastatic Adenocarcinoma: Comparison between Transcatheter Arterial Chemoembolization versus Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2009, 20, 360-367.	0.2	72
33	Selective Internal Radiation Therapy-induced Extrahepatic Injury. American Journal of Surgical Pathology, 2009, 33, 963-975.	2.1	67
34	Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 200-215.	0.6	26
35	Radioembolization (Yttrium-90 Microspheres) for Primary and Metastatic Hepatic Malignancies. Cancer Journal (Sudbury, Mass), 2010, 16, 163-175.	1.0	80
36	Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. Insights Into Imaging, 2010, 1, 167-181.	1.6	21

#	Article	IF	Citations
37	Safety of Yttrium-90 Microsphere Radioembolization in Patients with Biliary Obstruction. Journal of Vascular and Interventional Radiology, 2010, 21, 1213-1218.	0.2	14
38	Agreement between Competing Imaging Measures of Response of Hepatocellular Carcinoma to Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2010, 21, 515-521.	0.2	38
39	Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology, 2010, 138, 52-64.	0.6	925
40	Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM). Nuclear Medicine and Biology, 2010, 37, 861-867.	0.3	28
41	Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiologia Medica, 2010, 115, 619-633.	4.7	38
42	Use of Yttrium-90 Microspheres in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2010, 21, 1377-1384.	0.2	44
43	Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2010, 21, 1205-1212.	0.2	136
44	Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. Journal of Experimental and Clinical Cancer Research, 2010, 29, 70.	3.5	86
45	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.2	185
46	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	0.6	566
47	Radioembolization for Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 422-431.	0.6	91
48	Yttrium-90 Radioembolization for the Treatment of Primary and Metastatic Liver Tumors. Seminars in Roentgenology, 2011, 46, 159-165.	0.2	7
49	Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999â€“2009). Critical Reviews in Oncology/Hematology, 2011, 80, 393-410.	2.0	33
50	Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2011, 12, 1057-1073.	0.9	32
51	Radioembolization for hepatocellular carcinoma using TheraSphereÂ®. Saudi Journal of Gastroenterology, 2011, 17, 215.	0.5	4
52	Transcatheter Intraarterial Therapies: Rationale and Overview. Radiology, 2011, 259, 641-657.	3.6	206
53	Abstract No. 373: Tumor enhancement changes obersved by dual-phase cone beam CT (DPCBCT) before and immediately after glass microsphere Y90 radioembolization. Journal of Vascular and Interventional Radiology, 2012, 23, S149.	0.2	0
54	Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC. Cancer Treatment Reviews, 2012, 38, 641-649.	3.4	38

#	Article	IF	Citations
55	Availability of Yttrium-90 from Strontium-90: A Nuclear Medicine Perspective. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 621-641.	0.7	57
56	Radioembolization After Portal Vein Embolization in a Patient with Multifocal Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2012, 35, 1519-1523.	0.9	5
57	Development and evaluation of 90Y-labeled albumin microspheres loaded with magnetite nanoparticles for possible applications in cancer therapy. Journal of Materials Chemistry, 2012, 22, 24017.	6.7	27
59	Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: Evaluation of radiological and pathological response. Journal of Surgical Oncology, 2012, 105, 692-698.	0.8	76
60	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer, 2012, 118, 147-156.	2.0	250
61	Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2012, 138, 455-462.	1.2	20
62	Evolving Treatment Strategies for Management of Carcinoid Tumors. Current Treatment Options in Oncology, 2013, 14, 374-388.	1.3	10
63	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. Annals of Surgical Oncology, 2013, 20, 2518-2525.	0.7	76
64	Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?. Biomicrofluidics, 2013, 7, 011811.	1.2	16
65	Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know. Oncology, 2013, 84, 34-39.	0.9	16
66	Can C-Arm Cone-Beam CT Detect a Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and Carcinoid Liver Metastasis?. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 459-465.	0.7	18
68	Chemoembolization and Radioembolization for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, 604-611.	2.4	83
69	Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology, 2013, 24, 74-80.	0.2	21
70	Reply to: Downstaging to liver resection by radioembolization: A difficult to reach strategy?. European Journal of Surgical Oncology, 2013, 39, 920-921.	0.5	0
71	Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience. Egyptian Journal of Radiology and Nuclear Medicine, 2013, 44, 215-222.	0.3	2
72	Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology, 2013, 24, 1189-1197.e2.	0.2	18
73	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology, 2013, 58, 2188-2197.	3.6	154
74	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. Oncology, 2013, 84, 311-318.	0.9	134

#	Article	IF	Citations
75	Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma Treated with Yttrium-90 Microsphere Radioembolization. ISRN Oncology, 2013, 2013, 1-8.	2.1	8
76	Yttrium-90 radioembolization of liver tumors: what do the images tell us?. Cancer Imaging, 2013, 13, 645-657.	1.2	45
78	Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with 90Y-Microspheres for Unresectable Liver Metastases. PLoS ONE, 2013, 8, e69448.	1.1	16
79	Results in Hepatocellular Carcinoma. Medical Radiology, 2013, , 105-117.	0.0	2
80	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. Journal of Hepatocellular Carcinoma, 2014, 1, 163.	1.8	15
81	SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepatic Oncology, 2014, 1, 265-283.	4.2	12
82	Side Effects of Yttrium-90 Radioembolization. Frontiers in Oncology, 2014, 4, 198.	1.3	134
83	Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients. International Journal of Surgery, 2014, 12, 1403-1408.	1.1	20
84	Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 2014, 60, 192-201.	3.6	237
85	Prospective randomized pilot study of Y90+/â^'sorafenib as bridge to transplantation in hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 309-317.	1.8	80
86	Outpatient Single-Session Yttrium-90 Glass Microsphere Radioembolization. Journal of Vascular and Interventional Radiology, 2014, 25, 266-270.	0.2	53
87	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 486-493.	3.3	21
88	Transarterial Chemoembolization and Yittrium-90 for Liver Cancer and Other Lesions. Clinics in Liver Disease, 2014, 18, 877-890.	1.0	10
89	Chemoembolization and radioembolization. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 909-919.	1.0	19
90	99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1965-1975.	3.3	106
91	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1025-1031.	0.4	43
92	Functional Volumetric MRI in Assessing Treatment Response to Intra-Arterial Therapy of Primary and Secondary Liver Tumors. Journal of Computer Assisted Tomography, 2014, 38, 513-517.	0.5	6
93	Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. BioScience Trends, 2015, 9, 289-298.	1.1	56

#	Article	IF	Citations
94	Management of hepatocellular carcinoma with portal vein thrombosis. World Journal of Gastroenterology, 2015, 21, 3462.	1.4	90
95	Transarterial approaches to primary and secondary hepatic malignancies. Nature Reviews Clinical Oncology, 2015, 12, 481-489.	12.5	37
96	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology and Hepatology, 2015, 9, 335-348.	1.4	51
97	Advances in SPECT for Optimizing the Liver Tumors Radioembolization Using Yttrium-90 Microspheres. World Journal of Nuclear Medicine, 2015, 14, 75-80.	0.3	13
98	Yttrium-90 Radioembolization of Hepatocellular Carcinomaâ€"Performance, Technical Advances, and Future Concepts. Seminars in Interventional Radiology, 2015, 32, 388-397.	0.3	7
99	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 16-25.	4.2	40
100	In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver International, 2015, 35, 627-635.	1.9	84
101	Risk of Liver Abscess Formation in Patients with Prior Biliary Intervention Following Yttrium-90 Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 397-400.	0.9	33
102	Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World Journal of Hepatology, 2015, 7, 1553.	0.8	37
103	Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 401-420.	1.0	28
104	⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. Journal of Nuclear Medicine, 2015, 56, 1079-1087.	2.8	77
105	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal of Radiology, 2015, 88, 20140564.	1.0	26
106	Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. Hpb, 2015, 17, 52-65.	0.1	19
107	Bland Liver Tumor Embolization Complicated by Hepatic Abscess. Seminars in Interventional Radiology, 2015, 32, 323-328.	0.3	1
108	Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America, 2015, 53, 973-984.	0.9	9
110	Radioembolization with yttrium-90 microspheres work up: Practical approach and literature review. Diagnostic and Interventional Imaging, 2015, 96, 547-562.	1.8	29
111	Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Translational Gastroenterology and Hepatology, 2016, 1, 34-34.	1.5	20
112	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World Journal of Gastroenterology, 2016, 22, 7289.	1.4	138

#	Article	IF	Citations
113	Use of Yttrium-90 Radioembolization for Management of Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2016, 12, 226-231.	1.0	1
114	Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. CardioVascular and Interventional Radiology, 2016, 39, 1580-1588.	0.9	91
115	The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Advances in Radiation Oncology, 2016, 1, 351-364.	0.6	56
116	Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of Vascular and Interventional Radiology, 2016, 27, 1329-1336.	0.2	20
117	Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2016, 27, 1123-1129.	0.2	23
118	Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer, 2016, 5, 162-174.	4.2	53
119	⁹⁰Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	2.8	79
120	Hepatic imaging following intra-arterial embolotherapy. Abdominal Radiology, 2016, 41, 600-616.	1.0	30
121	Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology, 2017, 27, 526-535.	2.3	54
122	Comparison of the Adverse Event Profile of TheraSphereÂ® with SIR-SpheresÂ® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. CardioVascular and Interventional Radiology, 2017, 40, 1033-1043.	0.9	39
123	Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1383-1391.	0.9	9
124	Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Seminars in Interventional Radiology, 2017, 34, 109-115.	0.3	12
125	Imaging of Hepatocellular Carcinoma Response After ⁹⁰Y Radioembolization. American Journal of Roentgenology, 2017, 209, W263-W276.	1.0	29
126	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control, 2017, 24, 107327481772924.	0.7	29
127	Radioembolisation of hepatocellular carcinoma: a primer. Clinical Radiology, 2017, 72, 1002-1013.	0.5	25
128	Fluoroscopic Radiation Exposure in Chemoembolization and Radioembolization: Results from a Prospective Randomized Study. Journal of Vascular and Interventional Radiology, 2017, 28, 1272-1273.	0.2	4
129	Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes. Journal of Nuclear Medicine, 2017, 58, 104S-111S.	2.8	43
131	Yttriumâ€90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World Journal of Surgery, 2017, 41, 241-249.	0.8	57

#	Article	IF	Citations
132	Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma. PLoS ONE, 2017, 12, e0181488.	1.1	23
133	Locoregional and systemic therapy for hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 215-228.	0.6	64
134	Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Translational Gastroenterology and Hepatology, 2017, 2, 98-98.	1.5	20
135	Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surgery and Nutrition, 2017, 6, 44-48.	0.7	34
136	Sources, behaviour, and environmental and human health risks of high-technology rare earth elements as emerging contaminants. Science of the Total Environment, 2018, 636, 299-313.	3.9	440
137	Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology, 2018, 129, 112-122.	0.3	80
138	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000â€patient 15â€year experience. Hepatology, 2018, 68, 1429-1440.	3.6	174
139	Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastasesâ€‹. Journal of Gastrointestinal Oncology, 2018, 9, 311-315.	0.6	20
140	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Seminars in Liver Disease, 2018, 38, 242-251.	1.8	95
141	Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nuclear Medicine and Molecular Imaging, 2019, 53, 367-373.	0.6	21
142	Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS ONE, 2019, 14, e0216935.	1.1	31
143	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Frontiers in Pharmacology, 2019, 10, 450.	1.6	26
144	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. Techniques in Vascular and Interventional Radiology, 2019, 22, 93-99.	0.4	13
145	Recent advances in radiotherapy and its associated side effects in cancerâ€”a review. Journal of Basic and Applied Zoology, 2019, 80, .	0.4	63
146	Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT. CardioVascular and Interventional Radiology, 2020, 43, 295-301.	0.9	10
147	Optimization of the radiolabelling method for improved in vitro and in vivo stability of 90Y-albumin microspheres. Applied Radiation and Isotopes, 2020, 156, 108984.	0.7	3
148	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers, 2020, 12, 1914.	1.7	72
149	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology, 2020, 2, 113-125.	0.1	2

#	Article	IF	Citations
150	Outpatient Yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiologia Medica, 2020, 125, 971-980.	4.7	16
151	Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review. Cancers, 2020, 12, 294.	1.7	22
152	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Annals of Surgical Oncology, 2021, 28, 1499-1510.	0.7	3
153	Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology, 2021, 32, 211-219.	0.2	6
154	Percutaneous Implantation of a Microcatheter-Port System for Hepatic Arterial Infusion Chemotherapy of Unresectable Liver Tumors: Technical Feasibility, Functionality, and Complications. Diagnostics, 2021, 11, 399.	1.3	3
155	Current Status and Future Direction of Hepatic Radioembolisation. Clinical Oncology, 2021, 33, 106-116.	0.6	16
156	Locoregional Therapies for Bridging and Downstaging Hepatocellular Carcinoma Prior to Liver Transplant. , 0, , 127-144.		0
157	Post-administration dosimetry in yttrium-90 radioembolization through micro-CT imaging of radiopaque microspheres in a porcine renal model. Physics in Medicine and Biology, 2021, 66, 095011.	1.6	5
158	Radioembolization for Metastatic Neuroendocrine Tumors. Digestive Disease Interventions, 0, 05, .	0.3	0
159	Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules, 2021, 26, 3966.	1.7	29
160	Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer, 2021, 10, 433-450.	4.2	9
161	Yttrium-90 Radioembolotherapy for Hepatocellular Cancer. , 2011, , 319-335.		4
162	131 I-labeled chitosan hydrogels for radioembolization: A preclinical study in small animals. Nuclear Medicine and Biology, 2017, 52, 16-23.	0.3	7
163	Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. Hpb, 2014, 16, 336-341.	0.1	30
164	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 2016, 11, e0154986.	1.1	48
165	68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies. PLoS ONE, 2016, 11, e0164626.	1.1	16
166	A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget, 2017, 8, 5460-5473.	0.8	1
167	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11234.	0.5	31

#	Article	IF	Citations
168	Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World Journal of Gastroenterology, 2008, 14, 1664.	1.4	96
169	Conventional transarterial chemoembolizationvsmicrosphere embolization in hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology, 2014, 20, 17206.	1.4	33
170	Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies. World Journal of Gastroenterology, 2016, 22, 3006.	1.4	5
171	Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2015, 6, 469-78.	0.6	47
172	Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surgery and Nutrition, 2014, 3, 185-93.	0.7	17
173	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World Journal of Hepatology, 2015, 7, 738.	0.8	48
174	Radioembolization for unresectable liver cancer: initial experiences at a single center and review of the literature.. Diagnostic and Interventional Radiology, 2009, 16, 70-8.	0.7	22
175	Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Seminars in Interventional Radiology, 2021, 38, 432-437.	0.3	3
176	Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Seminars in Interventional Radiology, 2021, 38, 438-444.	0.3	2
178	Possible role of the scintigraphic estimation of the relative liver perfusion in the diagnosis and therapy of liver carcinomas. Acta Chirurgica Iugoslavica, 2011, 58, 33-38.	0.0	0
179	Tumors of the Liver and Biliary Tract. , 2013, , 451-472.		1
180	90Yttrium Microsphere Radioembolization for Liver Malignancies: A Technical Overview. Journal of Postgraduate Medicine Education and Research, 2013, 47, 61-64.	0.1	0
182	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2016, , 1-24.		0
183	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2017, , 1337-1360.		0
184	HCC Radioembolization with Yttrium-90 Polymer Beads (SIR-Spheres). , 2018, , 127-136.		0
185	Radionuclide Therapy for Tumors of the Liver and Biliary Tract. , 2019, , 859-879.		0
186	Treatment of Hepatocellular Carcinomas by Hepatic Transarterial Chemoembolization, Case Presentation and Review of the Literature. Acta Medica Transilvanica, 2020, 25, 32-35.	0.1	0
187	Progress in research of hepatocellular carcinoma with tumor thrombus. World Chinese Journal of Digestology, 2019, 27, 1239-1247.	0.0	0

#	Article	IF	Citations
188	Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy. Chinese Chemical Letters, 2022, 33, 3492-3496.	4.8	6
189	Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. Clinical and Translational Oncology, 2022, 24, 796-808.	1.2	4
190	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. CardioVascular and Interventional Radiology, 2022, 45, 1599-1607.	0.9	21
191	Unusual Radiotracer Deposition to the Forearm After Intrahepatic Injection of 99mTc-Macroaggregated Albumin Using a Transradial Approach. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	0.7	0
193	Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model. EJNMMI Physics, 2022, 9, 21.	1.3	10
194	MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdominal Radiology, 2022, 47, 2299-2313.	1.0	4
195	The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer. Nuclear Medicine Communications, 2022, 43, 807-814.	0.5	2
196	SIRT in 2025. CardioVascular and Interventional Radiology, 2022, 45, 1622-1633.	0.9	6
197	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2022, , 1515-1545.		0
198	A Workflow for Dosimetry of 90Y Radioembolization Based on Quantitative 99mTc-MAA SPECT/CT Imaging and a 3D-Printed Phantom. Applied Sciences (Switzerland), 2022, 12, 10541.	1.3	4
199	Optimization of 99mTc-MAA SPECT/CT Imaging for 90Y Radioembolization Using a 3D-Printed Phantom. Applied Sciences (Switzerland), 2022, 12, 10022.	1.3	1
200	Simplification of dosimetry in 90Y-radioembolization therapy by dual planar images. BMC Cancer, 2022, 22, .	1.1	0
201	Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2023, 32, 101736.	0.2	2
202	Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treatment Reviews, 2023, 115, 102526.	3.4	1
210	Role of Transarterial Radioembolization in Management of HCC. , 0, , .		0